Novo Nordisk

Novo Nordisk profit up 8%; warns on sales growth
Marketwatch
Thu, 05/1/14 - 08:29 am
earnings
Novo Nordisk
Can Once Daily GLP-1 Lyxumia Be The Next Major Growth Driver For Sanofi?
Seeking Alpha
Wed, 04/16/14 - 09:37 am
Lyxumia
GLP-1 agonist
Sanofi
Novo Nordisk
diabetes
Victoza
Makings of a Wide Moat in Diabetes Care
Morningstar
Fri, 03/28/14 - 11:16 am
diabetes
Takeda
Sanofi
GSK
Victoza
Merck
insulin
Novo Nordisk
Afrezza
U300
Tresiba
Eli Lilly
Novo CEO sees improved picture for Tresiba in U.S. market
Fierce Pharma
Mon, 03/24/14 - 12:13 pm
Novo Nordisk
Pharma CEOs
Tresiba
diabetes
Sanofi
insulin
Novo Nordisk sees chance of U.S. Tresiba launch before rival products
Yahoo/Reuters
Thu, 03/20/14 - 05:35 pm
Novo Nordisk
insulin
diabetes
Tresiba
Lantus
Sanofi
Eli Lilly
Novo reports positive results from phase 3 trial with NovoEight
Reuters
Wed, 03/19/14 - 04:11 pm
Novo Nordisk
NovoEight
hemophilia A
Novo Nordisk taps bankers for potential IT unit spinoff
Fierce Pharma
Tue, 03/18/14 - 12:16 pm
Novo Nordisk
spinoffs
Europe’s Half-Empty Pharma Market
WSJ Online
Mon, 03/17/14 - 10:55 am
Europe
Bayer
Novo Nordisk
Shire
Merck KGaA
Novo Nordisk - An Opportune Time To Book Profits
Seeking Alpha
Fri, 03/14/14 - 08:36 am
Novo Nordisk
With Solvadi in the mix, the FDA's class of 2013 is set for chart-busting sales
Fierce Pharma
Tue, 03/11/14 - 12:00 pm
Sovaldi
FDA
Gilead Sciences
Novo Nordisk
AbbVie
Biogen Idec
Can Diabetes Treatments Replace Patent Losses At Eli Lilly & Co?
Motley Fool
Thu, 03/6/14 - 10:17 am
Eli Lilly
diabetes
patents
dulaglutide
GLP-1 agonist
Novo Nordisk
AstraZeneca
GSK
JNJ
FDA eases worries regarding certain diabetes medications
Yahoo/Fly on the Wall
Thu, 02/27/14 - 08:19 am
FDA
diabetes
Merck
Januvia
Janumet
Novo Nordisk
Victoza
Bristol-Myers Squibb
Byetta
Bydureon
Who loses most in Lilly vs. Novo diabetes study? AstraZeneca
Fierce Pharma
Wed, 02/26/14 - 07:03 pm
Victoza
Novo Nordisk
Eli Lilly
dulaglutide
diabetes
Bydureon
AstraZeneca
Lilly weekly diabetes drug succeeds vs market leader Victoza -study
Yahoo/Reuters
Tue, 02/25/14 - 08:15 am
Eli Lilly
diabetes
Victoza
Novo Nordisk
dulaglutide
Biotech Showdown: Arena Pharmaceuticals vs. VIVUS Inc.
Motley Fool
Fri, 02/21/14 - 10:44 am
obesity
Arena Pharmaceuticals
Vivus
Belviq
Qsymia
Novo Nordisk
Orexigen
Novo Nordisk targets Mexico for early obesity drug launch
Fierce Pharma
Wed, 02/19/14 - 12:57 pm
Novo Nordisk
obesity
Mexico
liraglutide
Poor Pipeline Management Imperils Lilly's Future Cash Flows
Motley Fool
Mon, 02/17/14 - 03:22 pm
Eli Lilly
diabetes
insulin
Novo Nordisk
Sanofi
oncology
Alzheimer's disease
What's Big Pharma's latest hot spot? The Middle East
Fierce Pharma
Tue, 02/11/14 - 12:00 pm
Middle East
Merck
Merck Serono
Sanofi
Novo Nordisk
Eli Lilly
Bayer
Is There Investment Upside In The Future Of Treating Diabetes?
Seeking Alpha
Mon, 02/10/14 - 08:43 am
diabetes
MannKind
Merck
Novo Nordisk
NeoStem
Regeneron
Novo Nordisk Gives anti-NKG2A Rights to Innate
Yahoo/Zacks.com
Thu, 02/6/14 - 06:09 pm
Innate Pharma S.A.
Novo Nordisk
anti-NKG2A

Pages